A retrospective study evaluating effect of neuropsychiatric adverse events on discontinuation rates in women and older patients infected with HIV.
Phase of Trial: Phase IV
Latest Information Update: 02 Jan 2017
At a glance
- Drugs Dolutegravir (Primary) ; Elvitegravir; Raltegravir
- Indications HIV infections
- Focus Adverse reactions
- 02 Jan 2017 New trial record